Clinical trial
PS-341 in Combination With Herceptin in Advanced Breast Cancer That…
NCT00199212 · Jules Bordet Institute, Other · Completed
Key facts
| NCT number | NCT00199212 |
|---|---|
| Title | PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2 |
| Official title | A Phase I, Open Label, Dose-escalating Study of the Proteasome Inhibitor PS-341 in Combination With Two Schedules of Herceptin, in Patients With Advanced Breast Cancer That Overexpresses HER-2 |
| Lead sponsor | Jules Bordet Institute, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoma Breast Stage IV |
| Intervention type | Drug |
| Interventions | Combination of trastuzumab and PS-341 |
| Enrollment | 19 |
| Start date | Oct 1, 2003 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Sep 20, 2005 |
| Last update posted | Feb 24, 2011 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: